Purple Biotech Ltd is a clinical-stage company with a focus on developing therapies for cancer patients in the U.S. Their oncology pipeline includes CM24, a monoclonal antibody in Phase 1b/2 clinical trials for non-small cell lung cancer and pancreatic cancer combination therapy, and NT219, a small molecule in Phase 1/2 trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company, previously known as Kitov Pharma Ltd, is based in Rehovot, Israel.